Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells

Molecular Cancer Research

Volumn 6, Issue 8, 2008, Pages 1308-1315

  Doudican, Nicole ^a   Rodriguez, Adrianna ^a   Osman, Iman ^a,b   Orlow, Seth J ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; FENBENDAZOLE; MEBENDAZOLE; OXIBENDAZOLE; PROTEIN BAX; PROTEIN BCL 2; SMALL INTERFERING RNA; BENZIMIDAZOLE DERIVATIVE; TUBULIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG SCREENING; GENE INACTIVATION; HUMAN; HUMAN CELL; IC 50; IMMOBILIZED CELL; MELANOCYTE; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; ANIMAL; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECT; DRUG RESISTANCE; METABOLISM; MICROTUBULE; MITOCHONDRION; PATHOLOGY; PHOSPHORYLATION; PROTEIN BINDING; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BENZIMIDAZOLES; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; MEBENDAZOLE; MELANOCYTES; MELANOMA; MICE; MICROTUBULES; MITOCHONDRIA; PHOSPHORYLATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-BCL-2; TUBULIN;

EID: 52449109127     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-07-2159     Document Type: Article

References (43)

1. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003;22:3138-51.
2. Helmbach H, Rossmann E, Kern MA, Schadendorf D. Drug-resistance in human melanoma. Int J Cancer 2001;93:617-22.
3. Zhuang L, Lee CS, Scolyer RA, et al. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod Pathol 2007;20:416-26.
4. Tchernev G, Orfanos CE. Downregulation of cell cycle modulators p21, p27, p53, Rb and proapoptotic Bcl-2-related proteins Bax and Bak in cutaneous melanoma is associated with worse patient prognosis: preliminary findings. J Cutan Pathol 2007;34:247-56.
5. Martarelli D, Pompei P, Baldi C, Mazzoni G. Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice. Cancer Chemother Pharmacol 2008;61:809-17.
6. Mukhopadhyay T, Sasaki J, Ramesh R, Roth JA. Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. Clin Cancer Res 2002;8:2963-9.
7. Sasaki J, Ramesh R, Chada S, Gomyo Y, Roth JA, Mukhopadhyay T. The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. Mol Cancer Ther 2002;1:1201-9.
8. Bowling BD, Doudican N, Manga P, Orlow SJ. Inhibition of mitochondrial protein translation sensitizes melanoma cells to arsenic trioxide cytotoxicity via a reactive oxygen species dependent mechanism. Cancer Chemother Pharmacol. Epub 2008 Feb 23.
9. 6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl) 1-nitrosourea, and cisplatin. J Pharmacol Exp Ther 2003;304:661-8.
10. Fernández Y, Verhaegen M, Miller TP, et al. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res 2005;65:6294-304.
11. Grant SW, Kyshtoobayeva AS, Kurosaki T, Jakowatz J, Fruehauf JP. Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma. Cancer Detect Prev 1998;22:185-94.
12. Kroumpouzos G, Eberle J, Garbe C, Orfanos CE. P53 mutation and c-fos overexpression are associated with detection of the antigen VLA-2 in human melanoma cell lines. Pigment Cell Res 1994;7:348-53.
13. Blagosklonny MV, Giannakakou P, el-Deiry WS, et al. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 1997;57:130-5.
14. Haldar S, Basu A, Croce CM. Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells. Cancer Res 1998;58:1609-15.
15. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci U S A 1995;92:4507-11.
16. Vermox (Janssen). In: Sifton D, editor. Physicians' Desk Reference. Montvale (NJ): Medical Economics Data Company; 1995. p. 1203-4.
17. Lacey E. The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles. Int J Parasitol 1988;18:885-936.
18. Sajid MS, Iqbal Z, Muhammad G, Iqbal MU. Immunomodulatory effect of various anti-parasitics: a review. Parasitology 2006;132:301-13.
19. Reuter S, Jensen B, Buttenschoen K, Kratzer W, Kern P. Benzimidazoles in the treatment of alveolar echinococcosis: a comparative study and review of the literature. J Antimicrob Chemother 2000;46:451-6.
20. Müller E, Akovbiantz A, Ammann RW, et al. Treatment of human echinococcosis with mebendazole. Preliminary observations in 28 patients. Hepatogastroenterology 1982;29:236-9.
21. Pourgholami MH, Woon L, Almajd R, Akhter J, Bowery P, Morris DL. In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole. Cancer Lett 2001;165:43-9.
22. Morris DL, Jourdan JL, Pourgholami MH. Pilot study of albendazole in patients with advanced malignancy. Effect on serum tumor markers/high incidence of neutropenia. Oncology 2001;61:42-6.
23. Nogales E. Structural insight into microtubule function. Annu Rev Biophys Biomol Struct 2001;30:397-420.
24. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996;56:816-25.
25. Yvon AM, Wadsworth P, Jordan MA. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 1999;10:947-59.
26. Hadfield J, Ducki S, Hirst N, McGowan A. Tubulin and microtubules as targets for anticancer drugs. Prog Cell Cycle Res 2003;5:309-25.
27. Li Y, McClay EF. Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol 2002;29:413-26.
28. 3H]mebendazole binding to tubulin by structurally diverse microtubule inhibitors which interact at the colchicine binding site. Biochem Mol Biol Int 1995;35:1153-9.
29. Nogales E. Structural insights into microtubule function. Annu Rev Biochem 2000;69:277-302.
30. Criado Fornelio A, Rodriguez Caabeiro F, Jimenez Gonzalez A. The mode of action of some benzimidazole drugs on Trichinella spiralis. Parasitology 1987;95:61-70.
31. Lacey E. Mode of action of benzimidazoles. Parasitol Today 1990;6:112-5.
32. Göker H, Ozden S, Yildiz S, Boykin DW. Synthesis and potent antibacterial activity against MRSA of some novel 1,2-disubstituted-1H-benzimidazole-N-alkylated-5-carboxamidines. Eur J Med Chem 2005;40:1062-9.
33. Andrzejewska M, Yépez-Mulia L, Cedillo-Rivera R, et al. Synthesis, antiprotozoal and anticancer activity of substituted 2-trifluoromethyl- and 2-pentafluoroethylbenzimidazoles. Eur J Med Chem 2002;37:973-8.
34. Sharma S, Abuzar S. The benzimidazole anthelmintics - chemistry and biological activity. Prog Drug Res 1983;27:85-161.
35. Cerroni L, Soyer HP, Kerl H. bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. Am J Dermatopathol 1995;17:7-11.
36. Selzer E, Schlagbauer-Wadl H, Okamoto I, Pehamberger H, Pötter R, Jansen B. Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines. Melanoma Res 1998;8:197-203.
37. Korsmeyer SJ. BCL-2 gene family and the regulation of programmed cell death. Cancer Res 1999;59:1693-700s.
38. Wacheck V, Losert D, Günsberg P, et al. Small interfering RNA targeting bcl-2 sensitizes malignant melanoma. Oligonucleotides 2003;13:393-400.
39. Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006;24:4738-45.
40. Ito T, Deng X, Carr B, May WS. Bcl-2 phosphorylation required for antiapoptosis function. J Biol Chem 1997;272:11671-3.
41. Bennett DC, Cooper PJ, Hart IR. A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int J Cancer 1987;39:414-8.
42. Manga P, Orlow SJ. Inverse correlation between pink-eyed dilution protein expression and induction of melanogenesis by bafilomycin A1. Pigment Cell Res 2001;14:362-7.
43. Huerta S, Goulet EJ, Huerta-Yepez S, Livingston EH. Screening and detection of apoptosis. J Surg Res 2007;139:143-56.